FBIO vs AVXL

Analysts rate Fortress Biotech, Inc.

(FBIO) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Anavex Life Sciences Corp.

(AVXL) delivered a total return of -72. 4%, compared to -95. 9% for Fortress Biotech, Inc. (FBIO). Over 10 years, the gap is even starker: AVXL returned -25. 7% versus FBIO's -94. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Fortress Biotech, Inc.

(FBIO) is the lower-risk stock at 0. 97β versus Anavex Life Sciences Corp. 's 1. 51β — meaning AVXL is approximately 55% more volatile than FBIO relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Fortress Biotech, Inc.

grew EPS 68. 2% year-over-year, compared to -3. 8% for Anavex Life Sciences Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Anavex Life Sciences Corp.

(AVXL) is the more profitable company, earning 0. 0% net margin versus -79. 8% for Fortress Biotech, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AVXL leads at 0. 0% versus -191. 4% for FBIO. At the gross margin level — before operating expenses — FBIO leads at 63. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, FBIO (1.

4% yield) pays a dividend. AVXL does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Fortress Biotech, Inc.

(FBIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 97), 1. 4% yield). Anavex Life Sciences Corp. (AVXL) carries a higher beta of 1. 51 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FBIO: -94. 8%, AVXL: -25. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

FBIO pays a dividend while AVXL does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.